Amarin Corp (AMRN) Pressured Early as Vascepa Orange Book Decision Delayed...Again

Go back to Amarin Corp (AMRN) Pressured Early as Vascepa Orange Book Decision Delayed...Again

Amarin (AMRN) Said No FDA NCE Decision in August Orange Book

September 10, 2012 5:10 PM EDT

Amarin Corp Plc (NASDAQ: AMRN) said after the close of trading Monday that it does not expect an FDA NCE decision by the next Orange Book, due on our about September 14, 2012.

From the filing:

Typically, the U.S. Food and Drug Administration (FDA) publishes a determination on the... More

UPDATE: Jefferies Maintains a 'Buy' on Amarin Corporation (AMRN); Orange Book Update

August 20, 2012 7:13 AM EDT

(Updated - August 20, 2012 7:38 AM EDT)

Jefferies maintains a 'Buy' on Amarin Corporation (NASDAQ: AMRN) price target of $28.00.

Analyst, Thomas Wei, said, "The FDA issued the July Orange Book update including Vascepa, indicating the FDA has yet to make a determination on NCE status. We believe the FDA may need additional time to consider AMRNs unique arguments, which we view positively. While many investors remain focused on the NCE decision, we... More

Amarin (AMRN) Wins FDA Approval of Vascepa

July 26, 2012 5:44 PM EDT

Amarin Corporation plc (Nasdaq: AMRN) announced the U.S. FDA has approved Vascepa^TM (icosapent ethyl) capsules (formerly known as AMR101) as an adjunct to diet to reduce triglyceride (TG) levels in adult... More